Status:
COMPLETED
A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This study is not being conducted in the United States. The purpose of the study is to evaluate the effects of nateglinide compared to glibenclamide on renal hemodynamics and albumin excretion.
Eligibility Criteria
Inclusion
- Type 2 diabetes diagnosed at least 1 year before inclusion
- Blood glucose criteria must be met
- Microalbuminuria criteria must be met
Exclusion
- Pregnant or nursing females or females of childbearing potential not using a medically approved birth control method
- Blood glucose criteria outside the specified range
- Microalbuminuria criteria outside the specified range
- Serious cardiovascular events within the past 6 months
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00238472
Start Date
May 1 2003
End Date
June 1 2005
Last Update
April 27 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.